Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) just unveiled an update.
Recce Pharmaceuticals announced the successful dosing of all patients in its Phase II clinical trial for RECCE 327 topical gel, targeting acute bacterial skin and skin structure infections. Preliminary data suggest significant improvements in infection symptoms, with no serious adverse events reported. The company is planning further regulatory trials and a Phase III study in Australia, with a separate trial in Indonesia for diabetic foot infections, highlighting its strategic expansion and potential market impact in the ASEAN region.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. is a company focused on developing a new class of synthetic anti-infectives, targeting the treatment of bacterial infections. The company is working towards addressing the growing issue of antimicrobial resistance with its products, including broad-spectrum antibiotics effective against both Gram-positive and Gram-negative bacteria.
YTD Price Performance: -3.09%
Average Trading Volume: 155,249
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$109M
For an in-depth examination of RCE stock, go to TipRanks’ Stock Analysis page.
